Cencora Inc (COR) Stock Price, Quote & News

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distr...

Industry: Medical Distribution

Sector: Healthcare

Phone: 610 727 7000

Website: www.cencora.com

Address:

1 West First Avenue, Conshohocken, United States

BillionerOfKing Jan. 14 at 5:30 PM

$COR Current Stock Price: $348.91 Contracts to trade: $350 COR Jan 16 2026 Call Entry: $2.75 Exit: $3.49 ROI: 27% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

IN0V8 Jan. 13 at 6:02 PM

$COR Buy Baird raises target price to $415 from $392

0 · Reply

ZacksResearch Jan. 12 at 2:29 PM

$CAH, $MCK, and $COR are quietly outpacing the market — here’s why! 🚀 🔍 Cardinal Health’s double-digit earnings growth and pending acquisition of Solaris Health signal a robust turnaround with a Zacks Rank #2. 📈 McKesson’s scale drives a 10% revenue jump, and management raised full-year EPS guidance with a Zacks Rank #3. 💡 Cencora’s specialty focus and strategic investments for future growth underpin its Zacks Rank #3. Discover the full breakdown of these under-the-radar winners here 👉 https://www.zacks.com/stock/news/2815489/3-medical-supplies-stocks-that-beat-the-market-despite-macro-headwinds?cid=sm-stocktwits-2-2815489-body-28367&ADID=SYND_STOCKTWITS_TWEET_2_2815489_BODY_28367

0 · Reply

ZacksResearch Jan. 12 at 1:29 PM

Three medical supplies stocks beating the market — even with macro pressure mounting 👀 $CAH, $MCK, and $COR are showing how scale, specialty focus, and strong execution can still deliver market-beating returns while macro headwinds pressure the broader space. Want to see what’s driving the outperformance? Full breakdown here 👉 https://www.zacks.com/stock/news/2815489/3-medical-supplies-stocks-that-beat-the-market-despite-macro-headwinds?cid=sm-stocktwits-2-2815489-teaser-28366&ADID=SYND_STOCKTWITS_TWEET_2_2815489_TEASER_28366

0 · Reply

SilentJoker34 Jan. 9 at 1:52 AM

$OTLK Did aezs have an approved drug in uk & Germany with revenues? With many more countries coming 2026-2027? Did aezs have a distribution contract with $COR ? Did aezs have 2 more drugs in phase 3 clinical trials? Fda isn't the end all be all...💎🧐🪖

1 · Reply

ZacksResearch Jan. 8 at 5:23 PM

$COR Positioned for Growth Despite Challenges Cencora’s U.S. Healthcare Solutions and specialty drug demand drive its growth prospects, with a projected 11.9% bottom-line improvement over the next five years. However, international segment weakness and competition pose challenges. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2814032/heres-why-you-should-retain-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2814032-body-28030&ADID=SYND_STOCKTWITS_TWEET_2_2814032_BODY_28030

0 · Reply

ZacksResearch Jan. 8 at 4:23 PM

$COR — why holding Cencora right now actually makes sense 📊 Cencora’s strength in U.S. Healthcare Solutions, rising specialty drug demand, and growing biosimilar adoption continue to support its growth outlook, even as competitive pressures and international weakness remain real headwinds. Get the full bull/bear case here 👉 https://www.zacks.com/stock/news/2814032/heres-why-you-should-retain-cencora-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2814032-teaser-28029&ADID=SYND_STOCKTWITS_TWEET_2_2814032_TEASER_28029

0 · Reply

TeresaOsterhoudt909 Jan. 6 at 5:13 PM

$CP $AJG $RACE $RSG $COR Great structure

0 · Reply

Creisi Jan. 5 at 4:08 PM

$AFL $COR $MLTX $REGN $SOC Another bullshit ad. MLTX is not a billboard for your bullshit ads. Fuck off! It's for MLTX news and discussion.

0 · Reply

CrazyChief Jan. 2 at 3:47 PM

$OTLK $COR Where is Bob???.?

1 · Reply

Cencora, Inc. (COR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 4:30 PM EST - 8 days ago

Cencora Announces Date and Time for First Quarter Fiscal 2026 Earnings Release

Dec 15, 2025, 7:11 AM EST - 4 weeks ago

Cencora to take majority control of OneOncology to expand cancer services

Dec 15, 2025, 7:00 AM EST - 4 weeks ago

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Dec 3, 2025, 7:30 AM EST - 6 weeks ago

Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities

Dec 2, 2025, 3:33 PM EST - 6 weeks ago

Cencora, Inc. (COR) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 2, 2025, 12:53 PM EST - 6 weeks ago

Cencora, Inc. (COR) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 7, 2025, 2:05 PM EST - 2 months ago

Cencora: Earnings Visibility Driving Re-Rating Potential

Nov 5, 2025, 4:01 PM EST - 2 months ago

Cencora, Inc. (COR) Q4 2025 Earnings Call Transcript

Nov 5, 2025, 7:44 AM EST - 2 months ago

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

Nov 5, 2025, 7:00 AM EST - 2 months ago

Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain

Nov 5, 2025, 7:00 AM EST - 2 months ago

Cencora Announces $1 Billion Investment to Strengthen Its U.S. Distribution Network

Nov 5, 2025, 6:30 AM EST - 2 months ago

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

Nov 1, 2025, 11:15 PM EDT - 2 months ago

ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November

ABBV ADP AEP AIZ AOS ATO BDX

Oct 16, 2025, 9:00 AM EDT - 3 months ago

IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes

Oct 14, 2025, 12:47 PM EDT - 3 months ago

The Market Took a Hit. These 6 Stocks Can Sidestep the Wreckage.

MCK WFC

Oct 6, 2025, 4:30 PM EDT - 3 months ago

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

Sep 10, 2025, 2:05 PM EDT - 4 months ago

Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 9, 2025, 6:02 PM EDT - 4 months ago

Cencora, Inc. (COR) Presents At Baird Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 11:11 AM EDT - 4 months ago

Cencora, Inc. (COR) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:15 PM EDT - 5 months ago

Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

Aug 12, 2025, 2:31 PM EDT - 5 months ago

Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap

Aug 8, 2025, 5:08 PM EDT - 5 months ago

Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy

Aug 6, 2025, 12:25 PM EDT - 5 months ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 7:51 AM EDT - 5 months ago

Cencora raises annual profit forecast on strong demand for specialty drugs

Aug 6, 2025, 6:30 AM EDT - 5 months ago

Cencora Reports Fiscal 2025 Third Quarter Results

Jul 3, 2025, 7:30 AM EDT - 6 months ago

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

May 28, 2025, 7:30 AM EDT - 8 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 16, 2025, 8:37 AM EDT - 8 months ago

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

May 7, 2025, 2:06 PM EDT - 9 months ago

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

May 7, 2025, 10:55 AM EDT - 9 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 6:30 AM EDT - 9 months ago

Cencora Reports Fiscal 2025 Second Quarter Results

Apr 4, 2025, 3:42 PM EDT - 10 months ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM

Mar 31, 2025, 7:35 AM EDT - 10 months ago

These 15 stocks are the most profitable companies in the S&P 500

AAPL ABBV AON BA CL CLX DVA

Mar 28, 2025, 7:00 AM EDT - 10 months ago

Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

Feb 26, 2025, 11:00 AM EST - 11 months ago

Cencora: Higher Potential Returns After Reduced Walgreens Stake

Feb 6, 2025, 8:37 PM EST - 1 year ago

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance

Feb 6, 2025, 8:30 PM EST - 1 year ago

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

WBA

Feb 6, 2025, 8:30 AM EST - 1 year ago

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

Feb 5, 2025, 11:40 AM EST - 1 year ago

Cencora (COR) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 7:23 AM EST - 1 year ago

Cencora raises 2025 profit forecast on specialty drug demand

Feb 5, 2025, 6:30 AM EST - 1 year ago

Cencora Reports Fiscal 2025 First Quarter Results

Jan 27, 2025, 7:30 AM EST - 1 year ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

HROW

Jan 13, 2025, 12:07 PM EST - 1 year ago

Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth

COST DHR EL MSGS WST

Jan 8, 2025, 7:30 AM EST - 1 year ago

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

Jan 2, 2025, 4:23 PM EST - 1 year ago

Cencora raises annual profit forecast

Jan 2, 2025, 4:15 PM EST - 1 year ago

Cencora Completes Acquisition of Retina Consultants of America

Dec 9, 2024, 4:15 PM EST - 1 year ago

Cencora Closes $1.8 Billion Senior Notes Offering

Dec 6, 2024, 8:30 AM EST - 1 year ago

Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers

Dec 5, 2024, 10:26 AM EST - 1 year ago

Cencora: Competitive Advantages Defined

BillionerOfKing Jan. 14 at 5:30 PM

0 · Reply

IN0V8 Jan. 13 at 6:02 PM

$COR Buy Baird raises target price to $415 from $392

0 · Reply

ZacksResearch Jan. 12 at 2:29 PM

0 · Reply

ZacksResearch Jan. 12 at 1:29 PM

0 · Reply

SilentJoker34 Jan. 9 at 1:52 AM

1 · Reply

ZacksResearch Jan. 8 at 5:23 PM

0 · Reply

ZacksResearch Jan. 8 at 4:23 PM

0 · Reply

TeresaOsterhoudt909 Jan. 6 at 5:13 PM

$CP $AJG $RACE $RSG $COR Great structure

0 · Reply

Creisi Jan. 5 at 4:08 PM

$AFL $COR $MLTX $REGN $SOC Another bullshit ad. MLTX is not a billboard for your bullshit ads. Fuck off! It's for MLTX news and discussion.

0 · Reply

CrazyChief Jan. 2 at 3:47 PM

$OTLK $COR Where is Bob???.?

1 · Reply

OfficialStocktwitsUser Dec. 31 at 6:23 PM

$COR RSI: 48.68, MACD: -2.3446 Vol: 3.26, MA20: 340.88, MA50: 348.07 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

DorotheaNewell809 Dec. 31 at 5:49 PM

$CP $AJG $RACE $RSG $COR Great structure

0 · Reply

Altairus Dec. 31 at 4:14 AM

$OTLK $COR

0 · Reply

NYC100 Dec. 31 at 4:13 AM

$OTLK $COR

1 · Reply

Knowledgeworthmore Dec. 26 at 9:21 PM

$OTLK Remember all, $OTLK has world largest global partner $COR for international marketing, we should adapt global market very easy and quick.

2 · Reply

PtolomeusPicks Dec. 24 at 6:23 PM

$COR Future valuation dynamics revolve around strategic clarity amid intensifying competitive pressure, with outcomes shaped by timing and discipline. Execution clarity would stabilize long‑term sentiment.

0 · Reply

ZacksResearch Dec. 24 at 4:37 PM

Wall Street is planting its flag on these 3 medical names for 2026 👀 Analysts are backing $COR, $ADUS and $SEM as long-term winners, pointing to AI adoption, rising home care demand, and facility expansion driving growth across the medical sector. Want to see why these three earned bullish support — and what could fuel their next leg higher? Full breakdown here 👉 https://www.zacks.com/stock/news/2808492/these-3-medical-stocks-have-wall-streets-bullish-vote-for-2026?cid=sm-stocktwits-2-2808492-teaser-26195&ADID=SYND_STOCKTWITS_TWEET_2_2808492_TEASER_26195

0 · Reply

Knowledgeworthmore Dec. 24 at 4:08 PM

$OTLK keep it in the mind theres few fda approved wet amd out there, market is huge only couple company having all the steak, if otlk get approved in the usa, its going to take most of the steak, cause they have very strong partner the $COR and its safer than others.

1 · Reply

ZacksResearch Dec. 24 at 3:37 PM

$COR, $ADUS, $SEM — Why these medical stocks could be among your best bets for 2026, according to analysts! 📈 ✨ Each boasts a Zacks Rank #2 (Buy) and VGM Score of A, with analysts highlighting strong operational strength and growth visibility. These stocks are well-positioned in the evolving healthcare landscape. See what makes them stand out here 👉 https://www.zacks.com/stock/news/2808492/these-3-medical-stocks-have-wall-streets-bullish-vote-for-2026?cid=sm-stocktwits-2-2808492-body-26194&ADID=SYND_STOCKTWITS_TWEET_2_2808492_BODY_26194

0 · Reply

DidYouReadThis Dec. 24 at 2:49 PM

Good luck $OTLK with the 12/31/25 PDUFA! Does 834 views seem low for a network meta-analysis? https://doi.org/10.3390/jmahp13040058 $COR

2 · Reply

OfficialStocktwitsUser Dec. 22 at 3:02 PM

$COR RSI: 38.69, MACD: -2.3099 Vol: 12.94, MA20: 348.52, MA50: 345.68 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Dec. 19 at 5:28 PM

$COR makes a bold $3.6B bet on oncology — smart move or near-term pain? ⚠️ Cencora’s acquisition of OneOncology deepens its pharma-centric strategy and expands community oncology solutions, strengthening the long-term growth outlook even as it pressures the stock in the short term. Get the full strategic breakdown and risk/reward here 👉 https://www.zacks.com/stock/news/2806884/cencora-to-acquire-oneoncology-to-expand-community-oncology-solutions?cid=sm-stocktwits-2-2806884-teaser-25691&ADID=SYND_STOCKTWITS_TWEET_2_2806884_TEASER_25691

0 · Reply

Market Cap	66.38B
Revenue (ttm)	321.33B
Net Income (ttm)	1.55B
EPS (ttm)	N/A
PE Ratio	20.99
Forward PE	19.05
Profit Margin	0.48%
Debt to Equity Ratio	4.38

Volume	757,480
Avg Vol	1,478,692
Day's Range	N/A - N/A
Shares Out	193.99M
Stochastic %K	82%
Beta	0.66
Analysts	Strong Sell
Price Target	$392.27